Firm advises underwriters, led by Goldman, Sachs & Co., in $308 million offering of clinical stage biopharmaceutical company Synageva’s common stock.
Synageva BioPharma Corp. recently announced that it has closed on its $308 million public offering of 3,450,000 shares of common stock. Willkie represented the underwriters, led by joint book-running managers Goldman, Sachs & Co. and J.P. Morgan Securities LLC, in the transaction. Massachusetts-based Synageva is a clinical stage biopharmaceutical company developing therapeutic products for life-threatening rare diseases. The deal was handled by partners Gregory Astrachan, Benjamin Nixon and Thomas Meloro; of counsel Martin Miller and associate Bonnie Tice.